

# CITATION REPORT

List of articles citing

**Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir**

**DOI: 10.2165/00003088-200544100-00003**  
**Clinical Pharmacokinetics, 2005, 44, 1035-50.**

**Source:** <https://exaly.com/paper-pdf/39421320/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
128	Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. <i>Aids</i> , <b>2006</b> , 20, 1131-9	3.5	35
127	Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. <b>2006</b> , 25, 809-14		20
126	Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. <b>2006</b> , 62, 523-6		48
125	Antiretroviral therapy 2006: pharmacology, applications, and special situations. <b>2006</b> , 29, 431-58		10
124	A single centre cohort experience with a new once daily antiretroviral drug. <b>2006</b> , 82, 343-6		5
123	Inhibitors of HIV-1 protease: 10 years after. <b>2006</b> , 16, 1067-1091		18
122	Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. <b>2006</b> , 50, 3801-8		77
121	Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. <b>2007</b> , 51, 335-7		26
120	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , <b>2007</b> , 21, 41-6	3.5	108
119	Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. <b>2007</b> , 51, 1431-9		22
118	Important considerations regarding antiretroviral therapy in HIV-positive women. <b>2007</b> , 1, 203-213		1
117	Atazanavir in plasma-exchange treatment. <i>Aids</i> , <b>2007</b> , 21, 884-5	3.5	1
116	Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile. <b>2007</b> , 2, 131-143		3
115	Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. <b>2007</b> , 63, 935-40		32
114	Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. <b>2008</b> , 5, 5		63
113	Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. <b>2008</b> , 66, 179-95		52
112	Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. <b>2008</b> , 30, 1794-805		3

111	[Pharmacology, pharmacokinetic features and interactions of atazanavir]. <b>2008</b> , 26 Suppl 17, 2-8	3
110	Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. <b>2008</b> , 24, 821-5	31
109	Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. <i>Expert Review of Clinical Pharmacology</i> , <b>2008</b> , 1, 115-27 <sup>8</sup>	15
108	Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. <b>2008</b> , 48, 553-62	35
107	Experience with tenofovir disoproxil fumarate for antiretroviral therapy. <b>2008</b> , 9, 1197-209	5
106	Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. <b>2008</b> , 3, 296-305	46
105	Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance. <b>2009</b> , 5, 563-78	6
104	The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. <b>2009</b> , 7, 801-5	2
103	Pharmacogenomics of CYP3A: considerations for HIV treatment. <b>2009</b> , 10, 1323-39	36
102	HSA binding of HIV protease inhibitors: a high-performance affinity chromatography study. <b>2009</b> , 32, 1625-31	16
101	A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. <b>2009</b> , 85, 402-8	30
100	Current and Novel Inhibitors of HIV Protease. <b>2009</b> , 1, 1209-39	83
99	Atazanavir: a review of its use in the management of HIV-1 infection. <b>2009</b> , 69, 1107-40	72
98	Clinical pharmacology, efficacy and safety of atazanavir: a review. <b>2009</b> , 5, 1455-68	28
97	Efficacy and safety of boosted atazanavir in HIV-infected, ARV-naive patients [results from 48/96 weeks Castle study. <b>2009</b> , 8, 5-8	
96	Atazanavir, a promising option in therapy in HIV infected patients with liver injury and hyperbilirubinemia [a case report. <b>2009</b> , 8, 23-25	
95	Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. <i>Aids</i> , <b>2010</b> , 24, 331-40	3.5 33
94	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. <b>2010</b> , 32, 782-6	34

93	Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 975-83	1.6	29
92	Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis. <b>2007</b> , 59, 1451-62		6
91	Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients. <b>2010</b> , 11, 666-9		5
90	Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. <b>2010</b> , 54, 614-9		23
89	The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS. <b>2010</b> , 1-74		5
88	DrugHerb Interactions in Patients with HIV/AIDS. <b>2010</b> , 291-303		
87	Dermatology of the patient with HIV. <b>2010</b> , 28, 355-68, Table of Contents		32
86	Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <b>2011</b> , 7, 457-77		28
85	Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 267-80	6.2	0
84	Second-Generation Approved HIV Protease Inhibitors for the Treatment of HIV/AIDS. <b>2011</b> , 169-204		2
83	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. <b>2011</b> , 7, 609-22		14
82	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 499-504	1.6	9
81	Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. <b>2011</b> , 100, 3636-54		51
80	Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. <b>2011</b> , 51, 368-77		33
79	Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. <b>2011</b> , 66, 2075-82		17
78	Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. <b>2011</b> , 55, 5746-52		9
77	Ritonavir-boosted protease inhibitors in HIV therapy. <b>2011</b> , 43, 375-88		82
76	The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. <b>2012</b> , 64, 803-33		78

75	Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. <b>2012</b> , 92, 575-83	41
74	Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. <b>2012</b> , 52, 922-31	29
73	Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient. <b>2012</b> , 26, 204-6	2
72	Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. <b>2012</b> , 136, 186-201	82
71	Efficacy of a clinical decision-support system in an HIV practice: a randomized trial. <b>2012</b> , 157, 757-66	29
70	Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. <b>2012</b> , 74, 336-45	10
69	Pharmacokinetics and the drug-target residence time concept. <b>2013</b> , 18, 697-707	143
68	Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. <b>2013</b> , 14, 449-52	6
67	Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. <b>2013</b> , 27, 216-22	3
66	Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. <b>2013</b> , 62, 164-70	37
65	Effect of the African Traditional Medicine, <i>Sutherlandia frutescens</i> , on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir. <b>2013</b> , 2013, 324618	7
64	Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. <b>2013</b> , 57, 2265-71	22
63	The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. <b>2013</b> , 35, 71-7	14
62	[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. <b>2013</b> , 133, 463-71	1
61	Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study. <b>2013</b> , 7, 729-39	5
60	Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS. <b>2014</b> , 2014, 482693	8
59	Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers. <b>2014</b> , 76, 64-9	7
58	Direct spectroscopic evidence of hyperconjugation unveils the conformational landscape of hydrazides. <b>2014</b> , 53, 13756-9	22

57	Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. <b>2014</b> , 54, 1063-71		16
56	Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. <b>2014</b> , 15, 224-32		5
55	Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. <b>2014</b> , 24, 195-203		31
54	Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy. <b>2014</b> , 2014, 724958		4
53	Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. <b>2014</b> , 21, 1115-42		336
52	A systematic review of the use of atazanavir in women infected with HIV-1. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 293-307	1.6	4
51	Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 449-51	1.6	3
50	Direct Spectroscopic Evidence of Hyperconjugation Unveils the Conformational Landscape of Hydrazides. <b>2014</b> , 126, 13976-13979		4
49	Organic carbamates in drug design and medicinal chemistry. <b>2015</b> , 58, 2895-940		346
48	Medication Adherence and Health Outcomes of People Living with HIV Who Are Food Insecure and Prescribed Antiretrovirals That Should Be Taken with Food. <b>2015</b> , 4, 79		27
47	Treatment outcomes among people living with HIV who are food insecure and prescribed antiretrovirals taken with food. <b>2015</b> , 6, 35-40		15
46	Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults. <b>2016</b> , 35, 1333-1335		2
45	Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. <b>2017</b> , 50, 789-797		4
44	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <b>2017</b> , 87, 30-36		5
43	Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. <b>2017</b> , 49, 327-332		3
42	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <b>2017</b> , 55, 71-82		36
41	Synthesis and Reactivity of 5-Substituted Furfuryl Carbamates via Oxanorbornadienes. <b>2017</b> , 19, 2833-2836		6
40	Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?. <b>2017</b> , 31, 245-253		2

39	Food and Drug Interactions. <b>2017</b> , 7, 1-9		27
38	Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. <b>2018</b> , 828, 97-102		9
37	Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration. <b>2018</b> , 73, 185-191		2
36	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <b>2018</b> , 32, 431-441		11
35	Selected Food/Herb-Drug Interactions: Mechanisms and Clinical Relevance. <b>2018</b> , 25, e423-e433		17
34	Precision medicine for HIV: where are we?. <b>2018</b> , 19, 145-165		9
33	Protective Effect of Atazanavir Sulphate Against Pulmonary Fibrosis In Vivo and In Vitro. <b>2018</b> , 122, 199-207		14
32	PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics. <b>2018</b> , 28, 127-137		4
31	Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles. <b>2018</b> , 10,		33
30	The dawn of precision medicine in HIV: state of the art of pharmacotherapy. <b>2018</b> , 19, 1581-1595		8
29	Influence of and polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. <b>2019</b> , 20, 517-527		3
28	Management of Virologic Failure and HIV Drug Resistance. <i>Infectious Disease Clinics of North America</i> , <b>2019</b> , 33, 707-742	6.5	20
27	Drug-Drug Interactions in Prostate Cancer Treatment. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e71-e82	3.3	8
26	Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. <i>Therapeutics and Clinical Risk Management</i> , <b>2020</b> , 16, 595-605	2.9	31
25	Review on Preclinical and Clinical Evidence of Food (Beverages, Fruits and Vegetables) and Drug Interactions: Mechanism and Safety. <i>Current Drug Therapy</i> , <b>2020</b> , 15, 12-27	0.7	1
24	Analysis of plants lipids. <b>2020</b> , 677-705		1
23	The ADME Encyclopedia. <b>2021</b> , 1-9		
22	Maraviroc exposure is influenced by exogenous thyrotoxicosis. <i>Aids</i> , <b>2021</b> , 35, 701-703	3.5	

21	Antiretroviral Drugs Impact Autophagy with Toxic Outcomes. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
20	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. <i>Saudi Pharmaceutical Journal</i> , <b>2020</b> , 28, 1333-1352	4.4	11
19	Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123670	3.7	22
18	Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. <i>Current Topics in Medicinal Chemistry</i> , <b>2019</b> , 19, 1571-1598	3	22
17	Chapter 15:Development of Anti-HIV Drugs. <i>RSC Biomolecular Sciences</i> , <b>2010</b> , 291-318		
16	Cytochrome P450 Enzymes. 1		
15	Atazanavir. <b>2010</b> , 2830-2841		
14	Pharmacology and Pharmacokinetic Properties of Available Antiretrovirals. <b>2016</b> , 15-25		
13	Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 1-10	3.8	
12	Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 733935	5.6	2
11	SIMULTANEOUS ESTIMATION OF ATAZANAVIR SULFATE AND RITONAVIR IN MARKETED FORMULATIONS UV SPECTROSCOPIC THREE WAVELENGTH METHOD. <i>Indian Drugs</i> , <b>2018</b> , 55, 58-61	0.2	1
10	Different Schiff Bases-Structure, Importance and Classification.. <i>Molecules</i> , <b>2022</b> , 27,	4.8	15
9	Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.. <i>Iranian Journal of Pharmaceutical Research</i> , <b>2021</b> , 20, 278-288	1.1	
8	Unraveling enhanced brain delivery of paliperidone-loaded lipid nanoconstructs: pharmacokinetic, behavioral, biochemical, and histological aspects.. <i>Drug Delivery</i> , <b>2022</b> , 29, 1409-1422	7	1
7	Role of the Inhibitory Quotient in HIV Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 879-892	1.6	22
6	Drug-Drug and Food-Drug Interactions. <b>2022</b> , 448-456		0
5	A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.		1
4	Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals. <b>2023</b> , 29,		0



- 3 Food-Drug Interactions. **2023**, 21-37 ○
- 2 How to use COVID-19 antiviral drugs in patients with chronic kidney disease. 14, ○
- 1 Strategies to improve the physicochemical properties of peptide-based drugs. **2023**, 40, 617-632 ○